UpcomingPDUFA target action date

Relacorilant

Corcept Therapeutics (CORT)

Marketer take

A resubmission decision for the same molecule already approved as Lifyorli in ovarian cancer, so watch for distinct branding and for whether endocrinology messaging on hypercortisolism screening expands with it.

Sponsor company
Corcept Therapeutics (CORT)
Indication
Cushing's syndrome (resubmitted NDA)
Therapeutic area
Endocrinology
Event
PDUFA target action date
Date
Dec 17, 2026
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move